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Salivaricin G32, a 2667Da novel member of the SA-FF22 cluster of lantibiotics, has been puriﬁed and characterized from
Streptococcus salivarius strain G32. The inhibitory peptide diﬀers from the Streptococcus pyogenes—produced SA-FF22 in the
absence of lysine in position 2. The salivaricin G32 locus was widely distributed in BLIS-producing S. salivarius, with 6 (23%)
of 26 strains PCR-positive for the structural gene, slnA. As for most other lantibiotics produced by S. salivarius, the salivaricin
G32 locus can be megaplasmid encoded. Another member of the SA-FF22 family was detected in two Streptococcus dysgalactiae
of bovine origin, an observation supportive of widespread distribution of this lantibiotic within the genus Streptococcus. Since the
inhibitory spectrum of salivaricin G32 includes Streptococcus pyogenes, its production by S. salivarius, either as a member of the
normal oral microﬂora or as a commercial probiotic, could serve to enhance protection of the human host against S. pyogenes
infection.
1.Introduction
The Streptococcus pyogenes (Lanceﬁeld group A strepto-
coccus)-derived streptococcin A-FF22 (SA-FF22) was the
ﬁrst of the streptococcal bacteriocins to be isolated [1]a n d
then characterized both chemically [2, 3] and genetically
[4, 5]. Prior to its complete characterization, it was already
apparent that SA-FF22 was closely similar to the well-known
Lactococcus lactis bacteriocin, nisin [1]. Nisin, a widely-
u s e db i o p r e s e r v a t i v ea g e n t ,i sr e g a r d e da st h ep r o t o t y p eo f
the lantibiotics, a heterogeneous group of lanthionine-
containing bacteriocins produced by a wide variety of Gram-
positive bacteria. Strain FF22, the producer of the 26-amino
acid 2791Da SA-FF22, gives a characteristic bacteriocin
production ([P]-type) inhibitory pattern referred to as 436
when tested against a set of nine standard indicator bacteria
in a standardized deferred antagonism bacteriocin-typing
protocol [6].
The SA-FF22 genetic locus comprises nine open reading
frames arranged in three operons responsible, respectively,
for SA-FF22 regulation, biosynthesis, and immunity [7].
Interestingly,immediatelydownstreamoftheSA-FF22struc-
tural gene (scnA), there is another open reading frame-
designatedscnA  whichhasclosesimilaritytoscnA.Although
this reading frame has been shown to be transcribed [7], its
function has not been established. The inducing factor
for upregulation of SA-FF22 production has also not been
identiﬁed. Many lantibiotics, such as nisin [8] and salivaricin
A[ 9], have been shown to function as the signal peptides
for their own upregulation. In the present study we have
attemptedtoidentifythesignalfortheregulationofSA-FF22
transcription and show that this is not the SA-FF22 peptide.2 International Journal of Microbiology
Relatively recently a lantibiotic peptide identical to SA-
FF22 was shown to be produced by the food-grade species
Streptococcus macedonicus and named macedocin [10]. In
screening tests of streptococcal strains for their production
of bacteriocin-like inhibitory substances (BLISs), we have
detected a number of P-type 436 strains in the species Strep-
tococcus salivarius, Streptococcus mutans, and Streptococcus
dysgalactiae [11]. In the present study we show that the agent
responsible for the P-type 436 BLIS activity of S. salivarius
G32 is a SA-FF22-like peptide named salivaricin G32.
2.MaterialsandMethods
2.1. Bacterial Strains and Culture Conditions. All strains were
maintained on Columbia blood agar base (Difco, Sparks,
MD) supplemented with 5% human blood and 0.1%wt/vol.
CaCO3 (BACa) with incubation in 5% CO2 in air at 37◦C.
Liquidculturemedia wereTodd Hewittbroth(THB)(Difco)
and THB supplemented with CaCO3 (4μmol·L−1)a n dg l u -
cose (0.1%wt/vol.) (THBCaGlu). S. pyogenes strain FF22 [4]
and S. salivarius strain G32 were originally sourced from
human throat and human saliva, respectively. S. dysgalactiae
strains 61 and 67 were from bovine mastitis (courtesy of
Dr. B. Jayarao, University of Tennessee). The details of other
strains are listed in the tables in which they appear.
2.2. Screening for Antimicrobial Activity. BLIS activity was
detectedusingthedeferredantagonismmethodessentiallyas
originally described by Tagg and Bannister [6]. Brieﬂy, a
BACaplatewasseededfromonesidetotheotherwitha1cm
wide inoculum of the test strain from an 18hr BACa culture
using a cotton swab. Following incubation for 18hr at 37◦C
in 5% CO2 in air, the 1cm wide culture growth was removed
using a glass slide and the agar surface sterilised by exposure
to chloroform vapours for 30min, followed by airing for a
further 30min. Indicator bacteria (from 18hr THB cultures)
were then inoculated with a swab at right angles across the
line of the original diametric streak culture of the test strain
and the plate re-incubated for 18hr at 37◦Ci n5 %C O 2 in
air. Zones of inhibition were scored as − for no inhibition
or + if deﬁnite interference with the growth of the indicator
was evident. Variations to the deferred antagonism method
includedsupplementationoftheagarwitheither2mg·mL−1
Trypan Blue or 1% MgCl2, to test for interference of these
agents with BLIS activity.
2.3. Puriﬁcation of Salivaricin G32. C r u d ep r e p a r a t i o n so f
salivaricin G32 were obtained by freeze-thaw extraction of
80 lawn cultures of S. salivarius G32 that had been grown for
18hr at 37◦Ci n5 %C O 2 in air on tryptic soy broth (BBL)
supplemented with 2% yeast extract (Difco), 1% CaCO3,
and 0.7% Bacto agar adjusted to pH 6.5 before autoclaving
(TsYECa). The freeze thaw extraction process consisted of
the agar cultures (entire agar plate including bacterial lawn)
being frozen at −70◦C and then subsequently thawed.
The exudate on thawing was collected and clariﬁed by
centrifugation(15300×gfor25min).SalivaricinG32puriﬁ-
cation from this preparation (volume 2L) was essentially as
described previously for SA-FF22 [3]. The supernatant was
passed through an XAD-2 column (bed volume 330mL
Serva, Heidelburg) followed by washing with MQ water,
then one bed volume of each of 50% and 70% methanol.
The active peptide was eluted in one bed volume of 95%
methanol(pH2).Rotaryevaporation removedthemethanol
and the aqueous phase was clariﬁed by centrifugation at
5000× g for 15min prior to loading 500μL aliquots onto
aB r o w n l e eC 8 reversed phase (RP-300, Aquapore Octyl,
300 ˚ A, 7U) column. Elution of the inhibitory peptide was
achieved in a gradient of 18–30% acetonitrile over 60min
at 1mL/min pump speed using a Pharmacia FPLC system.
The active fractions (detected by spot test assay on a
lawn of Micrococcus luteus indicator I1) were pooled and
further fractionated by HPLC using a reversed phase C18
column (Phenomenex Jupiter C18,5 μm, 300 ˚ A, 250 ×
4.6mm) equilibrated in 0.1% triﬂuoroacetic acid. Elution
was in isocratic 45% acetonitrile over 60min. The active
fractions were pooled and analysed by Matrix Assisted Laser
DesorptionTimeofFlightMassSpectrometry(MALDI-TOF
MS). A sample of puriﬁed salivaricin G32 was subjected to
automated sequential Edman degradation on a gas-phase
proteinsequencerequippedwithanon-linemicroborePTH-
amino acid analyser (Applied Microsystems).
2.4.CloningandSequencingofsvnA. Totakeadvantageofthe
apparent close similarity of the salivaricin G32 peptide
sequence to that of the previously-identiﬁed SA-FF22, the
SA-FF22 primer pair scnF (5 -GCACCTATCCTTCTGAAG-
AAAG) and scnR (5 -GCACCTAGGCACATTTTTTCT-
TCC) was used to amplify the SA-FF22 structural gene,
and this was used to probe a series of chromosomal digests
of strain G32 (results not shown). A 1.9-Kb HindIII-EcoRI
derived restriction fragment containing the salivaricin G32
structural gene (slnA) was subsequently cloned into pUC19
using standard techniques [12] and sequenced. The LanM
universal primers [13] were used to sequence part of the
slnM gene in strain G32, and then PCR was used to close the
gap between slnA and slnM in order to obtain the complete
sequence of slnA1 (Figure 3).
2.5. Distribution of scnA and slnA in S. pyogenes and S.
salivarius. The species distribution of the SA-FF22 and sali-
varicin G32 structural genes was determined using PCR. All
ampliﬁcations were carried out using Hotmaster taq poly-
merase (Eppendorf, Hamburg, Germany). Typical PCR re-
actions consisted of 40.5μL PCR grade water (Eppendorf),
5μLo f1 0× Buﬀer (Hotmaster, Eppendorf), 1μL nucleotide
mix (Roche), 1μL each of the appropriate forward and
reverse primers (primer stocks at 0.01ng·μL−1), 0.5μLT a q
(Hotmaster 5U·μL−1), and 1μL of template DNA. Initial
denaturation at 95◦C for 2min was followed by 30 cycles of
95◦C for 30sec, annealing at 60◦C for 30sec and elongation
for 30sec at 65◦C. Two percent agarose gels were used to
analyse the PCR products.
2.6. Megaplasmid DNA Detection Using Pulsed Field Gel
Electrophoresis. Using previously described methods [14],International Journal of Microbiology 3
pulsedﬁeldgelelectrophoresis(PFGE)wasusedtodetectthe
megaplasmid DNA content of S. salivarius G32, S. salivarius
20P3, S. dysgalactiae 61, S. dysgalactiae 67, and S. pyogenes
FF22. One mL of 18hr THB cultures of the test strains was
used to inoculate 20mL THBs, which in turn were incubated
at 37◦Ci n5 %C O 2 in air to an optical density (650nm) of
0.5. The cells were then embedded in low-melting-point
agarose (SeaPlaque, FMC BioProducts, Rockland, ME, USA)
and lysed using 40mg lysozyme mL−1 (Roche), followed by
treatment with proteinase K (1mg·mL−1)( S i g m a ) .T h ep r o -
teinase K was removed by six 1hr TE (10mM Tris, 1mM
EDTA pH 7.5) washes with shaking (120rpm) at room
temperature. The DNA was separated using a CHEF-DR III
Pulsed Field Electrophoresis System (Bio-Rad) over 20hr
in a 1% agarose gel (Pulsed Field Certiﬁed Agarose, Bio-
Rad Laboratories). An initial pulse time of 6sec and ﬁnal of
18sec was used. The included angle (change in orientation
of the ﬁeld) was 120◦, and the gel was run at 4.5V·cm−1
with the buﬀer maintained at 14◦C. Gels were stained
with ethidium bromide (5mg·mL−1) and examined by UV
transillumination.
2.7. Induction of SA-FF22 and Salivaricin G32 Production.
The lantibiotic-producer strain (either S. pyogenes FF22 or S.
salivarius G32) was grown for 18hr in THB. Putative inducer
preparations (freeze thaw extracts of lawn cultures of strains
FF22, G32, EB1 (SA-FF22-negative derivative of strain FF22)
or strains of various other P-type designations) were added
as 20μL spots on the “test” side of a BACa plate and allowed
to dry into the agar. The lantibiotic producer strain was
then inoculated (by swabbing from the 18hr THB culture)
over the whole plate and incubated for a speciﬁed time.
Approximately 1-2hr before the bacteriocin produced by the
uninducedbacteriainthelawnculturewasexpectedtoattain
inhibitory levels; the bacterial growth was scraped from the
agar surface. On the “control” side of the plate, 20μLd r o p s
of inducer extracts equivalent to those previously deposited
on the “test side” were added and allowed to dry. The agar
surface was then sterilized with chloroform vapour. After
airing, an indicator strain culture was inoculated over the
entire agar surface and incubated. Zone sizes (diameter in
mm) were compared between the test and control halves
of the plate and induction was considered to have occurred
when, at a particular time, the test zone was at least twice
the width of the corresponding control zone. Diﬀerent
times for exposure to the putative inducer preparations were
evaluated in each experiment, depending on the anticipated
bacteriocin production characteristics of the strain under
investigation.
2.8.GenbankAccessionNumber. TheGenBankaccessionnu-
mber for the partial salivaricin G32 (sln)l o c u sf r o mS. sali-
varius strain G32 is JN831266.
3. Results/Discussion
3.1.InhibitoryActivityofS.salivariusG32. Applicationofthe
P-typing scheme allows for a preliminary categorization of
bacteriocin-producing strains on the basis of their inhibitory
proﬁle against nine standard indicator bacteria [6]. In this
test, S. salivarius G32 and S. dysgalactiae 61 both gave P-
type 436 inhibitory proﬁles identical to that of S. pyogenes
FF22 (Table 1). This can be considered to be a good pre-
liminary indication that all three strains produce closely-
similar inhibitory agents. A further indication of inhibitor
similarity was the apparent cross-immunity displayed when
each of these producers was tested for sensitivity to the
homologous (same strain) and heterologous (other two
strains) inhibitory products (Table 1) and also the failure
of all three strains to produce detectable inhibitory activity
when the P-typing medium was supplemented with either
2mg·mL−1 Trypan blue or 1% MgCl2,t w oa g e n t sp r e vi o u s l y
shown to speciﬁcally suppress SA-FF22 production by S.
pyogenes FF22 [22].
3.2. Puriﬁcation of Salivaricin G32. Salivaricin G32 was
puriﬁedtoapparenthomogeneityfromTsYECaagarcultures
using XAD-2 and a combination of C8 and C18 reversed
phase chromatography (Figure 1). MALDI-TOF MS anal-
ysis of the puriﬁed fraction identiﬁed a mass of 2667Da
(Figure 1), and Edman N-terminal sequencing revealed
a partial peptide sequence GNGVFKXIXHEXXLNXXAFL,
where X corresponds to an unidentiﬁable residue or blank
cycle. This amino acid sequence corresponds closely to that
of SA-FF22, the only diﬀerence being the absence of a
lysine residue at position two of the salivaricin G32 peptide
compared to the SA-FF22 peptide (Figure 2). On the basis
of the apparently closely-similar inhibitory spectra of strains
G32 and FF22, it appears that this lysine residue diﬀerence,
although changing the isoelectric point of the molecule, may
have relatively minimal impact on the target range of the
peptide.
3.3. Identiﬁcation of the Salivaricin G32 Structural Gene.
Attempts to amplify the salivaricin G32 structural gene using
primersdesignedtotheSA-FF22locuswereunsuccessfuland
soacloningapproachwastakenusingtheSA-FF22structural
gene scnA as a probe for Southern blotting. Following
sequencing of the region surrounding slnA, the salivaricin
G32 structural gene (slnA) was shown to be present as two
almost identical copies in strain G32 (Figure 3). An align-
ment of scnA, mcdA, and slnA and some other known
variants is shown in Figure 2. The predicted propeptide
resulting from translation of slnA diﬀers from SA-FF22 in
only the absence of a Lys residue in position 2 of the
salivaricin G32 propeptide. However, there are also ﬁve
diﬀerent amino acids in the predicted leader sequence
encoded by slnA and six diﬀerences in slnA  when compared
tothescnA-encodedleaderregion(Figure 2).Theﬁrst483bp
ofslnRwassequencedandthepredictedaminoacidsequence
showed85%identitytothecorrespondingregionencodedby
scnR.Similarly, translation of the ﬁrst 903bp of slnM showed
63% identity to that encoded by scnM. Based on these
comparisons,itappearsthatthereissigniﬁcantheterogeneity
within the processing genes for the SA-FF22-like lantibiotics4 International Journal of Microbiology
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Figure 1: Reversed phase fractionation of salivaricin G32 preparations. (a) Representative C8 reversed phase fractionation of concentrated
XAD-2 fractions containing inhibitory activity against indicator organism Micrococcus luteus. Elution of the column was with a gradient of
18–30% acetonitrile at a ﬂow rate of 1mL·min−1 with detection of absorbance at 214nm. (b) C18 reversed phase fractionation of pooled C8
reversed phase fractionated samples having inhibitory activity as indicated in panel A by the solid bar labelled 1. Elution was with isocratic
45% acetonitrile (containing 0.1% TFA) over 60 minutes at a ﬂow rate of 0.7mL·min−1. Active fractions (solid bar 2) from multiple runs
were pooled then analysed by MALDI-TOF MS as indicated by the grey insert.
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24 Salivaricin G32 (slnA)
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25 Macedocin (mcdA)
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G-N GVFKXIXH EXXLNXXAFL Salivaricin G32 (N-terminal
peptide sequence)
25 Salivaricin G32 (slnA)
26 Streptococcin A-FF22 (scnA)
26 Macedocin (mcdA)
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26 Macedocin (mcd  )   A
26 Streptococcin A-M49 (scn  )   A
26 Streptococcin A-M49 (scn  )   A
(b)
(1)
M KN N-KIHLEALEALQELK M EEID NLLGGA
ME E - - KMC L GA L NA L QE F Q I E E L DNL L GG
MKNNNK I CQDA L E S L QE L K L E E VDE L L GGA
29 Salivaricin G32 (slnA1)
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(a)
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Figure 2:(1)Alignmentof(a)theleadersequencesand(b)thepropeptidesequencesofsalivaricinG32,SA-FF22,andmacedocin(-indicates
a spacer introduced to aid the alignment). The N-terminal sequence derived from the puriﬁed G32 preparation is shown below, where X
indicates a blank cycle in the Edman reaction. (2) Alignment of (a) the predicted translated leader sequences and (b) the predicted translated
propeptidesequencesfor slnA1,scnA1,andmcdA1.Thenumberofaminoacidsineachsequenceisindicatedinfrontofeachsequencename.
indicating a considerable degree of compositional ﬂexibility
in a locus that appears to have dispersed widely amongst
a variety of streptococcal species.
3.4. Distribution of slnA and scnA in S. salivarius and S.
pyogenes. PCR detected slnA in 7 (23%) of 27 BLIS-pro-
ducing S. salivarius (Table 2). In S. pyogenes, only thirteen
(9%) of 144 tested strains of a wide variety of serotypes were
PCR-positive for scnA (Table 3). By contrast, 125 of the 144
S. pyogenes were determined to be positive for the salivaricin
As t r u c t u r a lg e n e( salA) (results not shown). Interestingly,
scnA-like genes were detected in some S. pyogenes strains6 International Journal of Microbiology
Table 2: Distribution of S. salivarius lantibiotic structural genes in S. salivarius strains of diﬀerent P-type designations.
S. salivarius strain P-type
Presence of salivaricin gene
Strain source/reference
slnA salA sboB sivA srtA-like∗
193 777 −−−− − [14]
20P3 677 + + −− − [15]
220 634 −−−+ − Laboratory collection of J. R.
Tagg
36 777 −−−− − [16]
5 677 + + − + − [16]
6 777 − ++−− [16]
9 676 − + − + − [16]
DC135 B 677 + + − ++ Laboratory collection of J. R.
Tagg
DC 156A 636 −−−+ − Laboratory collection of J. R.
Tagg
G32 436 + −−− + Laboratory collection of J. R.
Tagg
GR 677 − + −− − Laboratory collection of J. R.
Tagg
H7f 677 + + −− + Laboratory collection of J. R.
Tagg
H21 777 − ++−− [17]
H25 777 − ++−− Laboratory collection of J. R.
Tagg
JH 677 + + −− +[ 18]
JIM8777 226 −−−− − [19]
JIM8780 (CCHSS3) 636 −−−+ − [20]
JO-1 777 + −−+ − Laboratory collection of J. R.
Tagg
K12 777 − ++−− [21]
K30 777 − ++−− [17]
K-8P 226 −−−+ − Laboratory collection of J. R.
Tagg
M18 677 − + − + − [13]
Min5 777 − +++ − [17]
MPS 636 − + − ++ Laboratory collection of J. R.
Tagg
NR 777 −−+ −− [17]
Pirie 777 − + −− + Laboratory collection of J. R.
Tagg
Strong SA 777 − ++−− [17]
Total positive/total tested 7/27 17/27 8/27 11/27 6/27
∗A lantibiotic structural gene having close homology with the streptin lantibiotic gene srtA (O. Hyink, unpublished 2009).
that did not appear to produce SA-FF22-like P-type activity
such as the P-type 614 strain M57-71724, the P-type 324
strains M58-78234, M58-71726, M77-79305 and emm109-
99454, the P-type 577 strains emm83-60173 and emm113-
99458, the P-type 400 strain ST 2037-99448 and the BLIS-
negative (P-type 000) strains emm88-60183 and emm105-
99449. This indicates that in many S. pyogenes the SA-FF22
operon is incomplete, as has previously been shown to be the
case in S. pyogenes for the streptin and salivaricin A loci
[23, 24]. Interestingly, a selection of the S. pyogenes positive
for scnAbut apparently not producing SA-FF22 was found to
be resistant to SA-FF22 (strains M58-78234, M77-79305, ST
2037-99448, emm105-99449, and emm109-99454), indicat-
ing that the immunity component of the SA-FF22 locus was
functional for these strains and may provide an ecological
advantage in the presence of S. salivarius or S. pyogenes
producing SA-FF22-like inhibitors. In addition, it appears
that the salivaricin G32 locus can be expressed as part of a
battery of antimicrobial peptides in certain strains such as
S. salivarius strain T32 [14]. Four S. pyogenes strains A1020,International Journal of Microbiology 7
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Table 4: Screen of extracts for their potential to induce inhibitor production by members of the SA-FF22 family.
Inhibitor-positive preparation
tested for inducing activity
P-type of strain used as the source
of inhibitor preparation
Preparation induces inhibitor production in
S. pyogenes
FF22
S. salivarius
G32 S. dysgalactiae 61
S. pyogenes FF22 436 Yes Yes Yes
S. pyogenes EB1 000 No No No
S. salivarius G32 436 Yes Yes Yes
S. dysgalactiae 61 436 Yes Yes Yes
L. lactis C2102 636 No No No
S. mutans K24 636 No No No
S. mutans H10 777 No No No
S. mitis SK653 777 No No No
K. varians NCC1482 777 No No No
Salivaricin G32 (pure) 436 No No No
slnR slnA slnA1 slnM
scnK scnR scnA scnM scnT scnE scnE scnG
scn   A
sln   A
Figure 3:GraphicalrepresentationoftheSA-FF22locusillustrating
the section of the salivaricin G32 locus that has been sequenced.
Black-ﬁlled arrows indicate genes that have been completely
sequenced. Unﬁlled arrows indicate genes for which the complete
sequence has not yet been determined.
FF45, Min19, and Min52 were shown to have two copies of
scnA, an arrangement similar to that of the scnA locus in S.
pyogenes strain M49 and for the slnA locus in S. salivarius
strains G32 and JH.
These observations indicate that the production of sali-
varicin G32 could be a useful component of the anti-S. pyo-
genes armoury of S. salivarius probiotics. The antibacterial
spectrum of the SA-FF22 family of lantibiotics is known to
extend beyond streptococci to also include a broad variety of
potential pathogens and food spoilage bacteria such as Liste-
ria,Leuconostoc,andEnterococcus [10].Ashasbeenfoundfor
nisin-producing strains of the food grade species Lactococcus
lactis, BLIS-producing S. salivarius also has potential eﬃcacy
and applicability when added to foods as preservatives,
since they are known to be nonpathogenic [25]. Indeed the
widely-used BLIS-producing probiotic, S. salivarius strain
K12, has recently received self-aﬃrmed generally regarded
as safe (GRAS) status for addition to food in the USA.
One additional potential beneﬁt for the human consumer of
food containing salivaricin G32- (or macedocin-) producing
bacteria is that the coproduced induction peptide may boost
the BLIS activity of salivaricin G32-positive S. salivarius
presentintheconsumer’soralmicroﬂora,therebypotentially
providing increased protection against S. pyogenes,a sh a s
been previously reported for the stimulation of salivaricin
A production by the host’s indigenous microﬂora upon
ingestion of inducer peptide-containing milk [26].
3.5. Ampliﬁcation of an scnA-Like Gene in S. dysgalactiae . A
scnA-like gene was also detected in S. dysgalactiae strain 61
by PCR using primers designed to conserved regions of the
SA-FF22 and salivaricin G32 structural genes. The structural
gene in S. dysgalactiae strain 61 appeared identical to that in
strain FF22, although it is possible that the regions deﬁned
by these scnA-internal primers may diﬀer in strain 61. S.
dysgalactiae strain 61 was shown to produce a P-type of 436
and freeze-thaw extracts cross-induced production of both
SA-FF22 and G32 (Table 4).
3.6. Megaplasmid Detection Using Pulsed Field Gel Elec-
trophoresis. Analysis of S. salivarius G32, S. dysgalactiae 61,
and S. pyogenes FF22 showed megaplasmid DNA (ca. 170kb)
t ob ep r e s e n to n l yi ns t r a i nG 3 2( Figure 4). An apparently
intact salivaricin G32 locus has also been detected on a
220kb megaplasmid in S. salivarius strain JH, where it
comprises part of a lantibiotic island adjacent to loci encod-
ing salivaricin A and streptin [14] (N. Heng unpublished,
2011). It is interesting to note that S. pyogenes strain FF22
does not appear to contain megaplasmid DNA; however,
both S. dysgalactiae 61 and 67 have similar-sized (48kb)
exogenous DNA fragments (which may be bacteriophage or
plasmid). The S. salivarius megaplasmids do not therefore in
themselves appear to comprise the structural entity whereby
lantibiotic determinants translocate to other streptococcal
species, but rather, may act as repositories for lantibiotic-
encoding DNA acquired from other bacteria.
3.7. Induction of SA-FF22 and Salivaricin G32 Production.
The bacteriocin production of strains FF22, G32, and 61
was increased (induced) following the addition of freeze
thaw extracts from 18hr TsYECa cultures of either S. sali-
varius G32 or S. dysgalactiae 61 and also by 18hr THBInternational Journal of Microbiology 9
123 5 46 7
48.5
145
97
194(kb)
Figure 4: PFGE Analysis of megaplasmid content of total DNA
of S. salivarius strains G32 (lane 1), 20P3 (lane 2), S. dysgalactiae
strains 67 (lane 3), and 61 (lane 4), and S. pyogenes strain FF22
(lane 5). Lane 6 was left blank and lane 7 contained low range PFG
marker (New England Biolabs). Megaplasmid bands are indicated
with white arrows and marker sizes are indicated to the right of the
gel.
cultures of S. pyogenes strain FF22. No enhanced production
followed addition of extracts from strains having diﬀerent
P-type proﬁles or preparations of puriﬁed salivaricin G32
(Table 4). The inability of pure salivaricin G32 to induce
production of any of this family of SA-FF22 lantibiotics
indicates that the signal for upregulation of their production
is not the antimicrobial peptide itself, but rather, some
other molecule formed by the lantibiotic producer strain.
In an attempt to identify the inducing molecule, the SA-
FF22-like peptides from a strain FF22 THB culture were
separated by XAD-2 chromatography followed by anionic
exchange then reversed phase HPLC using a C18 column.
Individual fractions were assayed for induction of SA-FF22
production in the liquid induction assay. The inducing agent
initially copuriﬁed with fractions also exhibiting inhibitory
activity, but during C18 separation it eluted earlier (results
not shown). MALDI-TOF MS analysis of inducer active
fractions however, only detected peptide having the mass
of SA-FF22, indicating that the molecule responsible (even
when in very small amounts) for the induction of SA-
FF22 production may have copuriﬁed with residual (but
nevertheless subinhibitory) quantities of SA-FF22 present in
thatfraction.Thisisconsistentwithreportsthattheamounts
of inducer peptide required to induce other lantibiotic
systems are also extremely small [8]. Furthermore, the recent
report that macedocin is not an autoinducing molecule, but
rather that an αS1-casein medium component can serve to
induce macedocin production in laboratory-grown cultures
[27], lends further support to our contention that the SA-
FF22 family of lantibiotics may not be autoinducible.
References
[1] J. R. Tagg, R. S. Read, and A. R. McGiven, “Bacteriocin of a
group A streptococcus: partial puriﬁcation and properties,”
Antimicrobial Agents and Chemotherapy, vol. 4, no. 3, pp. 214–
221, 1973.
[2] J. R. Tagg, A. S. Dajani, L. W. Wannamaker, and E. D. Gray,
“Group A streptococcal bacteriocin: production, puriﬁcation,
and mode of action,” Journal of Experimental Medicine, vol.
138, no. 5, pp. 1168–1183, 1973.
[ 3 ]R .W .J a c k ,A .C a r n e ,J .M e t z g e re ta l . ,“ E l u c i d a t i o no ft h e
structure of SA-FF22, a lanthionine-containing antibacterial
peptide produced by Streptococcus pyogenes strain FF22,”
European Journal of Biochemistry, vol. 220, no. 2, pp. 455–462,
1994.
[4] J. R. Tagg and L. W. Wannamaker, “Genetic basis of strep-
tococcin A FF22 production,” Antimicrobial Agents and
Chemotherapy, vol. 10, no. 2, pp. 299–306, 1976.
[5] W. L. Hynes, J. J. Ferretti, and J. R. Tagg, “Cloning of the gene
encoding streptococcin A-FF22, a novel lantibiotic produced
by Streptococcus pyogenes, and determination of its nucleotide
sequence,” Applied and Environmental Microbiology, vol. 59,
no. 6, pp. 1969–1971, 1993.
[6] J. R. Tagg and L. V. Bannister, “‘Fingerprinting’ β-haemolytic
streptococci by their production of and sensitivity to
bacteriocine-like inhibitors,” Journal of Medical Microbiology,
vol. 12, no. 4, pp. 397–411, 1979.
[7] R. E. McLaughlin, J. J. Ferretti, and W. L. Hynes, “Nucleotide
sequence of the streptococcin A-FF22 lantibiotic regulon:
model for production of the lantibiotic SA-FF22 by strains of
Streptococcus pyogenes,” FEMS Microbiology Letters, vol. 175,
no. 2, pp. 171–177, 1999.
[8] O. P. Kuipers, M. M. Beerthuyzen, P. G. G. A. De Ruyter,
E. J. Luesink, and W. M. De Vos, “Autoregulation of nisin
biosynthesis in Lactococcus lactis by signal transduction,”
Journal of Biological Chemistry, vol. 270, no. 45, pp. 27299–
27304, 1995.
[9] M. Upton, J. R. Tagg, P. Wescombe, and H. F. Jenkinson,
“Intra- and interspecies signaling between Streptococcus sali-
varius and Streptococcus pyogenes mediated by SalA and SalA1
lantibiotic peptides,” Journal of Bacteriology, vol. 183, no. 13,
pp. 3931–3938, 2001.
[10] M. D. Georgalaki, E. Van den Berghe, D. Kritikos et al.,
“Macedocin, a food-grade lantibiotic produced by Streptococ-
cus macedonicus ACA-DC 198,” Applied and Environmental
Microbiology, vol. 68, no. 12, pp. 5891–5903, 2002.
[11] K. H. Dyet, “Subgrouping strains that produce inhibitory
activity similar to that of the lantibiotic Streptococcin A-
FF22,” Honours Dissertation, University of Otago, Dunedin,
New Zealand, 1999.
[12] J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular Cloning:
A Laboratory Manual, Cold Spring Harbor Laboratory, New
York, NY, USA, 2nd edition, 1989.
[13] P. A. Wescombe, M. Upton, P. Renault et al., “Salivaricin
9, a new lantibiotic produced by Streptococcus salivarius,”
Microbiology, vol. 157, no. 5, pp. 1290–1299, 2011.
[14] P. A. Wescombe, J. P. Burton, P. A. Cadieux et al., “Megaplas-
mids encode diﬀering combinations of lantibiotics in Strepto-
coccus salivarius,” International Journal of General and Molecu-
lar Microbiology, vol. 90, no. 3, pp. 269–280, 2006.
[15] K. F. Ross, C. W. Ronson, and J. R. Tagg, “Isolation and char-
acterization of the lantibiotic salivaricin A and its structural
gene salA from Streptococcus salivarius 20P3,” Applied and
Environmental Microbiology, vol. 59, no. 7, pp. 2014–2021,
1993.
[16] R.P.DempsterandJ.R.Tagg,“Theproductionofbacteriocin-
like substances by the oral bacterium Streptococcus salivarius,”
Archives of Oral Biology, vol. 27, no. 2, pp. 151–157, 1982.
[17] O.Hyink,P.A.Wescombe,M.Upton,N.Ragland,J.P.Burton,
and J. R. Tagg, “Salivaricin A2 and the novel lantibiotic sali-
varicin B are encoded at adjacent loci on a 190-kilobase trans-
missiblemegaplasmidintheoralprobioticstrainStreptococcus10 International Journal of Microbiology
salivanus K12,” Applied and Environmental Microbiology, vol.
73, no. 4, pp. 1107–1113, 2007.
[18] G. R. Tompkins and J. R. Tagg, “The ecology of bacteriocin-
producing strains of Streptococcus salivarius,” Microbial Ecol-
ogy in Health and Disease, vol. 2, pp. 19–28, 1989.
[19] C. Delorme, C. Poyart, S. D. Ehrlich, and P. Renault, “Extent
of horizontal gene transfer in evolution of streptococci of the
salivarius group,” Journal of Bacteriology, vol. 189, no. 4, pp.
1330–1341, 2007.
[20] L. De Vuyst and E. Vandamme, Bacteriocins of Lactic Acid
Bacteria: Microbiology, Genetics and Application,C h a p m a n
and Hall, Hampshire, England, 1994.
[21] J. P. Burton, P. A. Wescombe, C. J. Moore, C. N. Chilcott,
and J. R. Tagg, “Safety assessment of the oral cavity probi-
otic Streptococcus salivarius K12,” Applied and Environmental
Microbiology, vol. 72, no. 4, pp. 3050–3053, 2006.
[22] R. W. Jack and J. R. Tagg, “Factors aﬀecting production of
the group A streptococcus bacteriocin SA-FF22,” Journal of
Medical Microbiology, vol. 36, no. 2, pp. 132–138, 1992.
[23] P. A. Wescombe and J. R. Tagg, “Puriﬁcation and characteriza-
tion of streptin, a type a1 lantibiotic produced by streptococ-
cus pyogenes,” Applied and Environmental Microbiology, vol.
69, no. 5, pp. 2737–2747, 2003.
[ 2 4 ]P .A .W e s c o m b e ,M .U p t o n ,K .P .D i e r k s e ne ta l . ,“ P r o d u c t i o n
of the lantibiotic salivaricin A and its variants by oral
streptococci and use of a speciﬁc induction assay to detect
their presence in human saliva,” Applied and Environmental
Microbiology, vol. 72, no. 2, pp. 1459–1466, 2006.
[25] J. P. Burton, S. Cowley, R. R. Simon, J. McKinney, P. A.
Wescombe, and J. R. Tagg, “Evaluation of safety and human
tolerance of the oral probiotic Streptococcus salivarius K12:
A randomized, placebo-controlled, double-blind study,” Food
and Chemical Toxicology, vol. 49, no. 9, pp. 2356–2364, 2011.
[ 2 6 ]K .P .D i e r k s e n ,C .J .M o o r e ,M .I n g l i s ,P .A .W e s c o m b e ,a n dJ .
R. Tagg, “The eﬀect of ingestion of milk supplemented with
salivaricin A-producing Streptococcus salivarius on the bac-
teriocin-like inhibitory activity of streptococcal populations
on the tongue,” FEMS Microbiology Ecology, vol. 59, no. 3, pp.
584–591, 2007.
[27] M. Georgalaki, M. Papadelli, E. Chassioti et al., “Milk protein
fragments induce the biosynthesis of macedocin, the lantibi-
otic produced by Streptococcus macedonicus ACA-DC 198,”
Applied and Environmental Microbiology,v o l .7 6 ,n o .4 ,p p .
1143–1151, 2010.